BACKGROUND: Pertussis can cause significant morbidity in elderly patients, who can also
transmit this disease to infants and young children. There is little data available on the use of …

Summary On June 10, 2005, a tetanus toxoid, reduced diphtheria toxoid and acellular
pertussis vaccine (Tdap) formulated for use in adults and adolescents was licensed in the …

Primary immunization at 3, 4.5, and 6 months and boosting between 15 and 27 months of
age with combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus …

A total of 146 infants were immunised at ages 2, 3, and 4 months with a combined
diphtheria, tetanus, pertussis (DTP)--Haemophilus influenzae type b (Hib) tetanus toxoid …

Background. The high reactogenicity of whole cell pertussis vaccines discourages their use
in children. While acellular pertussis vaccines are less reactogenic, their use in diphtheria …

Objective: The aim of this open, multicenter, randomized trial was to evaluate the
immunogenicity and reactogenicity of a candidate combined diphtheria-tetanus-acellular …

Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) is recommended for all adults in
Canada but uptake is low. This study measured the knowledge, attitudes, beliefs, and …

Background Tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccination during
adolescence was introduced in response to the resurgence of pertussis in various countries …

Background The immunogenicity of acellular pertussis vaccines and persistence of immunity
after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) …

An understanding of the antibody persistence elicited by a combined tetanus, diphtheria, 5-
component acellular pertussis, and inactivated poliovirus vaccine (Tdap-IPV) after …